Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

Clinical trial NCT04712903 · COMPLETED

Trial details

NCT number: NCT04712903
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Small Cell Lung Carcinoma Extensive Disease

Start date: 2020-12-16
Primary completion: 2023-06-21
Enrollment: 101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.